Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Myasthenia Gravis Treatment Market Grown from 2024 to 2025?

In the preceding years, there has been a significant expansion in market size for treatment of myasthenia gravis. It’s projected to rise from $1.55 billion in 2024 to hit a market cap of $1.66 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The past growth can be traced back to cholinesterase inhibitors, the introduction of thymectomy procedures and immunosuppressive therapies, the development of plasma exchange operations, and the role of patient advocacy.

What Growth Rate Is Anticipated for the Myasthenia Gravis Treatment Market in the Coming Years?

The market size of myasthenia gravis treatment is projected to witness robust growth in the upcoming years. Its size is anticipated to expand to $2.26 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. The key factors contributing to this growth during the forecasted period include the utilization of biologics and monoclonal antibodies, gene and precision medicine, newly emerged immune modulators, neuroprotective approaches, and biosimilar medications. Noteworthy trends during the forecast period are likely to be digital therapeutics, joint research projects, a focus on patient-centered methods, application of real-world evidence, and the practice of extended safety monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

Who Are the Leading Companies in the Myasthenia Gravis Treatment Market?

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

What Are the Key Drivers of the Myasthenia Gravis Treatment Market?

An increase in the incidence of myasthenia gravis is anticipated to bolster the expansion of the market for myasthenia gravis treatment. Myasthenia gravis is identified as an autoimmune ailment that affects neuromuscular functioning, resulting in fatigue and skeletal muscle weakness in patients. The procedure involving medical service offerings and patient care to counteract myasthenia gravis is referred to as the myasthenia gravis treatment. Therefore, an increase in the occurrences of myasthenia gravis is enhancing myasthenia gravis treatment market sales. For example, the National Organization for Rare Disorders, a US-based entity aiding individuals with rare diseases, stated in January 2022 that the estimated prevalence of autoimmune myasthenia gravis was between 14 to 40 cases per 100,000 individuals in the US. In another instance, the American Journal of Managed Care, a peer-reviewed US journal, suggested in April 2024 that based on the average of 1,800 yearly diagnoses of myasthenia gravis, the estimated yearly incidence rate was 4.32 cases per 100,000 people, with a rate of 2.46 cases per 100,000 person-years. Hence, this spike in the myasthenia gravis cases is accompanied by a subsequent rise in the growth of the myasthenia gravis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11980&type=smp

What Are the Key Market Segments in the Myasthenia Gravis Treatment Industry?

The myasthenia gravis treatment market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Other Treatments

2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types

3) By End-Use: Hospitals, Clinics, Other End-Uses

Subsegments:

1) By Medication: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Corticosteroids

2) By Surgery: Thymectomy

3) By Other Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIg), Supportive Therapies

What Are the Latest Trends in the Myasthenia Gravis Treatment Market?

The myasthenia gravis treatment market is seeing a surge in product innovations, a key trend that is expected to grow in the future. The main companies in this market are concentrating on coming up with novel solutions in order to consolidate their market position. For example, UCB Pharma, which is a pharmaceutical firm from Belgium, received approval from the US FDA for Zilucoplan in October 2023. The drug is aimed at treating generalized myasthenia gravis (gMG) in adults showing positive results for anti-acetylcholine receptor (AChR) antibodies. This drug serves as a new possible solution for managing gMG, a disease manifesting through muscle weakness caused by an autoimmune response. ZILBRYSQ is particularly interesting as it is a self-administered, daily subcutaneous complement C5 inhibitor. This makes it a more convenient choice compared to the traditional intravenous treatments that have been the norm for treating gMG.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

What Are the Key Regional Markets in the Myasthenia Gravis Treatment Industry?

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11980

This Report Delivers Insight On:

1. How big is the myasthenia gravis treatment market, and how is it changing globally?

2. Who are the major companies in the myasthenia gravis treatment market, and how are they performing?

3. What are the key opportunities and risks in the myasthenia gravis treatment market right now?

4. Which products or customer segments are growing the most in the myasthenia gravis treatment market?

5. What factors are helping or slowing down the growth of the myasthenia gravis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model